Adamis (ADMP) Stock Should Be Up, Not Down, Following FDA Approval, Says Analyst

Yesterday afternoon, Adamis (ADMP) announced FDA approval of its lower dose version (0.15mg) of Symjepi for treatment of anaphylaxis in pediatric patients.

Adamis Pharma (ADMP) Stock: Next Stop, $7.50?

It’s a big day for Adamis Pharma (NASDAQ:ADMP). The drug maker announced a commercial partnership for its generic EpiPe Symjepi with Novartis (NYSE:NVS) subsidiary Sandoz, …

Adamis Pharmaceuticals Corp (ADMP): Analyst Sees Meaningful Revenue Gains Waiting in the Wings for Sympjepi Asset

Now that ADMP has submitted a PAS for its pediatric version of Symjepi, an epipnephrine injection cheaper than Mylan’s EpiPen, FBR’s Andrew D’silva sees a potential approval with less risk than the original version.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts